Literature DB >> 19208837

Mesenchymal stem cells: flip side of the coin.

Pravin J Mishra1, Prasun J Mishra, John W Glod, Debabrata Banerjee.   

Abstract

Tumor-associated fibroblasts or carcinoma-associated fibroblasts (CAF) play an important role in the growth of epithelial solid tumors. Although the cell type of origin of CAFs has not been conclusively established, it has been shown that they may be bone marrow derived. One side of the mesenchymal stem cell (MSC) coin is the well-accepted therapeutic potential of these cells for regenerative and immunomodulatory purposes. The ominous dark side is revealed by the recent work demonstrating that hMSCs may be a source of CAFs. In this review, we discuss the role of stromal cells in the tumor microenvironment and suggest that by exploring the in vitro/in vivo interplay between different cell types within the tumor milieu, strategies for improved tumor therapy can be developed.

Entities:  

Mesh:

Year:  2009        PMID: 19208837     DOI: 10.1158/0008-5472.CAN-08-3562

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  75 in total

Review 1.  Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands.

Authors:  Krisztian Nemeth; Balazs Mayer; Eva Mezey
Journal:  J Mol Med (Berl)       Date:  2009-09-13       Impact factor: 4.599

Review 2.  Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases.

Authors:  Farida Djouad; Carine Bouffi; Soufiane Ghannam; Danièle Noël; Christian Jorgensen
Journal:  Nat Rev Rheumatol       Date:  2009-07       Impact factor: 20.543

3.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Ivan Bertoncello; Zea Borok; Carla Kim; Angela Panoskaltsis-Mortari; Susan Reynolds; Mauricio Rojas; Barry Stripp; David Warburton; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2011-06

Review 4.  Wounds that will not heal: pervasive cellular reprogramming in cancer.

Authors:  Jung S Byun; Kevin Gardner
Journal:  Am J Pathol       Date:  2013-02-22       Impact factor: 4.307

Review 5.  The myofibroblast matrix: implications for tissue repair and fibrosis.

Authors:  Franco Klingberg; Boris Hinz; Eric S White
Journal:  J Pathol       Date:  2013-01       Impact factor: 7.996

Review 6.  Clinical applications of mesenchymal stem cells in laryngotracheal reconstruction.

Authors:  Summer Hanson; Susan L Thibeault; Peiman Hematti
Journal:  Curr Stem Cell Res Ther       Date:  2010-09       Impact factor: 3.828

7.  Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts.

Authors:  S M Goicoechea; R García-Mata; J Staub; A Valdivia; L Sharek; C G McCulloch; R F Hwang; R Urrutia; J J Yeh; H J Kim; C A Otey
Journal:  Oncogene       Date:  2013-03-25       Impact factor: 9.867

8.  Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.

Authors:  Lyndsay V Rhodes; James W Antoon; Shannon E Muir; Steven Elliott; Barbara S Beckman; Matthew E Burow
Journal:  Mol Cancer       Date:  2010-11-18       Impact factor: 27.401

9.  Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies.

Authors:  Cristina Marchini; Maura Montani; Georgia Konstantinidou; Rita Orrù; Silvia Mannucci; Giorgio Ramadori; Federico Gabrielli; Anna Baruzzi; Giorgio Berton; Flavia Merigo; Stefania Fin; Manuela Iezzi; Brigitte Bisaro; Andrea Sbarbati; Massimo Zerani; Mirco Galiè; Augusto Amici
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

10.  Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence.

Authors:  Pierre Perrot; Julie Rousseau; Anne-Laure Bouffaut; Françoise Rédini; Elisabeth Cassagnau; Frédéric Deschaseaux; Marie-Françoise Heymann; Dominique Heymann; Franck Duteille; Valérie Trichet; François Gouin
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.